MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.
Who can participate
Age range10 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders
* Patients with diagnosis of Parkinson's Disease
* Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank
* Diagnosis of Movement Disorder not related to Parkinson's Disease
* Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;
* Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;
* Diagnosis of Essential Tremor
* Willing to participate in the study, understand the procedures and sign the informed consent.
* Patients affected by cognitive impairment (CI) and dementia
* Diagnosis of probable:
* Lewy Body Dementia
* Alzheimer's Disease
* Mild Cognitive Decline
* Subjective memory complaints
* Willing to participate in the study, understand the procedures and sign the informed consent.
Exclusion Criteria:
* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.
What they're measuring
1
To monitor and predict the course of neurodegenerative diseases through the study of clinical markers and the creation of AI-models